Locations:
Search
Avoidance of septal reduction therapy continues while LVEF dysfunction remains infrequent
Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA
OPTION trial demonstrates significantly less bleeding risk with comparable efficacy
Aortic valve replacement is best option for lowering mortality in this high-risk population
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Novel approach outperforms standard of care for post-PVI stenosis and occlusion
27th offering of this CME favorite to be held March 6-9 in Hollywood, Florida
25-year series of over 1,000 patients reveals good long-term palliation, esophageal preservation
First-ever procedure restores patient’s health
New papers review the data and provide guidance on antiobesity medications and other options
Early learnings on use of the minimally invasive alternative to surgical bypass
Advertisement
Advertisement